By: Adam Feuerstein | 03/12/14 - 09:57 AM EDTUpdated from 6:14 am EDT with new information.
The clinical hold affects the remaining eight patients in the company`s Phase 2 study in essential thrombocythemia (ET) or polycythemia vera (PV) and the remaining two patients in the company`s Phase 2 study in multiple myeloma. In addition, the company's planned Phase 2 clinical trial in myelofibrosis will likely be delayed due to the clinical hold. It is possible that other studies using imetelstat, such as ongoing investigator-sponsored trials, may also be placed on clinical hold by the FDA.
Drug development would be so much easier if people didn't have livers. Adam Feuerstein (@adamfeuerstein) March 12, 2014Update: On a conference call this morning, Geron said the FDA concerns relate primarily to reports of "persistent" low-grade elevations in liver enzymes reported by almost all imetelstat-treated patients. Regulators want Geron to submit clinical data on the reversibility of these liver toxicity signals.
09/16/14 - 01:04 PM EDT
09/15/14 - 10:19 AM EDT
09/12/14 - 09:43 AM EDT
09/11/14 - 01:23 PM EDT
09/10/14 - 03:37 PM EDT
09/17/14 - 12:44 PM EDT
09/17/14 - 09:30 AM EDT
09/16/14 - 12:11 PM EDT
09/15/14 - 10:40 AM EDT
09/14/14 - 15:51 PM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.